Gout

Immunology · 3 drugs · 2 indications

Common inflammatory arthritis caused by uric acid crystal deposits in joints. Extremely painful flares. Affects ~9.2 million adults in the US (~4% of adults). While most patients are managed with allopurinol/febuxostat, ~1 million patients have "uncontrolled gout" where uric acid remains high despite oral therapy, leading to tophi (crystal deposits visible as lumps under skin) and progressive joint destruction.

Competitive Landscape (3 drugs)

Drug	Company	Mechanism	Modality	Route	Stage
NASP	SOBI	Tolerogenic nanoencapsulated uricase	Biologic (enzyme + nanoparticle)	IV	FILED
Pozdeutinurad	SOBI	URAT1 inhibitor	Small molecule	PO	PHASE3
KRYSTEXXA	AMGN	PEGylated uricase	PEGylated enzyme	IV	APPROVED

Indications (2)

Uncontrolled gout

NASP FILEDKRYSTEXXA APPROVED

Progressive and tophaceous gout

Pozdeutinurad PHASE3

Upcoming Catalysts

Pozdeutinurad - Progressive Gout - Ph3 - Topline (REDUCE-2)CLINICAL

SOBIQ2 2026

NASP - Uncontrolled Gout - FDA PDUFA DecisionREGULATORY

SOBIJune 27, 2026

Pozdeutinurad - Progressive Gout - Ph3 - Topline (REDUCE-1)CLINICAL

SOBIQ4 2026

Data from Supabase · Updated 2026-03-24